Infectious Diseases
COVID-19 has raised the importance of research into fighting infectious diseases that threaten populations.
COVID-19 vaccines: Post-authorisation safety surveillance
This whitepaper explores the multifaceted challenges of COVID-19 post-authorisation safety surveillance studies and how business intelligence tools can benefit these efforts.
Assessing strategies for mitigating infectious diseases
Public health officials turn to evidence as the basis for their health policies to control the spread of infections. However, many nuanced factors can influence variations in the number of infections caused by a single infected individual.
Watch the webinar: An introduction to infectious disease modelling
In this whitepaper, we explain the basic measures used to quantify infectious disease transmission and introduce the principles of dynamic modelling to inform the selection of the most effective and cost-efficient strategies for mitigating infectious diseases.
Fortifying vaccines: Preparation and prevention against future infectious disease epidemics
This whitepaper presents infrastructural and strategic considerations for strengthening vaccine development so that the medical community will be prepared to respond to future pandemics and novel diseases.
Antimicrobial resistance
The World Health Organization calls antimicrobial resistance, resulting from the overuse of antibiotics or other drugs, one of the top 10 public health threats. In fact, the next global pandemic could be another novel respiratory pathogen of zoonotic origins or a multidrug resistant strain of a previously eradicated pathogen.
In this whitepaper we provide a framework for understanding the antimicrobial crisis and the role healthcare and biopharma industries have to play in mitigating the impact of future pandemics.
The evolution of HIV treatments
HIV is highly heterogeneous, creating barriers to diagnosing and treating the disease. Moreover, the HIV epidemic varies by region and country, necessitating different clinical research strategies across geographies. In this whitepaper, we discuss opportunities for addressing these challenges, best practices for managing infectious disease clinical trials and recent developments in HIV treatment.
Pandemic respiratory vaccine clinical trials: A departure from business as usual
Vaccine trials for respiratory viruses, even in the best of circumstances, present a number of operational challenges for researchers, many of which are exacerbated in the face of a pandemic created by a novel virus. We focus on the corresponding success factors that can keep pandemic respiratory vaccine trials running at optimal speed and efficiency.
HIV infographic
HIV treatments: What has been achieved?
Before antiretroviral treatment availability, life expectancy for a person living with HIV was reduced by approximately 12.5 years. Now, this same individual will have near-normal life expectancy.
Infectious diseases and vaccines blogs
Beyond tradition: An analysis of modern vaccine technologies
This blog explores some of the most promising non-viral vaccine development platforms, highlighting their mechanisms, advantages, and limitations.
Why long-term follow-up should start early in vaccine trials
Learn more about why demonstrating long-term safety should start early in vaccine trials. With early planning, vaccine developers can gather real-world data and evidence needed to help individuals make informed decisions about vaccination.
Technology and tokenisation: Reflections from the 2025 World Vaccine Congress
Dive into the main themes, topics and outlooks from the 2025 WVC, held in Washington, D.C., where ICON presented and was recognised at the ViE Awards.
The race to develop combination vaccines – and the importance of indirect effects
A development race is currently underway in the field of combination vaccines, with a number of influential pharmaceutical and biotech companies pursuing combination vaccines targeting influenza and COVID-19.
Disease surveillance in low- and middle-income countries
Disease surveillance and reporting is critical to public health, enabling faster and better response to infectious disease outbreaks.
Disease surveillance and innovative vaccines
Learn about current approaches to disease surveillance and why they are important for the advancement of vaccine development in this blog.
Pre-emptive vaccine research to improve EID response
This blog explores strategies for strengthening vaccine development so that the medical community is better prepared to respond to future epidemics.
From clinician visits to data analysis: the challenges and solutions in COVID vaccine pharmacovigilance
Learn more about the challenges and solutions in assessing the long-term effects of Covid and Covid vaccines in this blog.
Infectious diseases and vaccines media contributions
-
Media article: Vaccine trials were run to the highest regulatory standards
Dr. Nuala Murphy, President of Clinical Research Services, discusses how ICON carried out the COVID-19 vaccine trials.
-
Media article: Pharma’s digital transformation – How to best incorporate wearables amid an evolving landscape
A thought leadership piece which examines how disruptions from COVID-19 have forced sponsors, clinicians and regulators to embrace digital's full potential to keep clinical trials moving forward.
-
Media article: Pfizer COVID vaccine trial proved remote monitoring, other innovations work, ICON CEO says
ICON CEO Steve Cutler discusses how the Pfizer COVID vaccine trial proves that starting clinical trials in weeks, as opposed to months, should be possible post-pandemic.
-
Media article: Rediscovering HIV: A new decade of research and innovation on the horizon
Dr. Caroline Forkin and Shelley McLendon discuss a new decade of research and innovation on the horizon for HIV.
-
Media article: What clinical holds and pauses mean for COVID-19 countermeasure timelines
ICON’s Nuala Murphy and David Morse discuss trial pauses and clinical halts after three high-profile COVID-19 trials are temporarily halted as a result of potential safety issues being flagged by independent Data and Safety Monitoring Boards.
-
Media article: The impact of influenza vaccination on the COVID-19 pandemic? Evidence and lessons for public health policies
Evidence and lessons for public health policies.
-
Media article: Treatment options for Clostridioides difficile
An immediate by-product of the COVID-19 pandemic has been an increase in antimicrobial-resistant infections, including Clostridioides difficile.
-
Media article: Here’s what we have to do to show a coronavirus vaccine works
The global effort to create a vaccine on such short notice is unprecedented.
Receive more insights on infectious diseases and vaccines from ICON
Please visit ICON's Preference Centre and select 'Infectious Diseases and Vaccines' under 'Therapeutic Areas of Interest' to receive new insights on infectious diseases and vaccines.
Infectious diseases and vaccines services
ICON’s extensive Infectious Disease expertise enables us to consistently select the best sites, expedite start-up timelines, and achieve enrolment targets for our clients. We apply proven strategies to clinical trials that minimise risk and generate high-quality, reliable data reducing the time and cost of bringing new therapies to market.